Clinical Cancer Research, Vol 1, Issue 10 1133-1138, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent

E Gupta, OI Olopade, MJ Ratain, R Mick, TM Baker, FK Berezin, AB Benson 3rd and ME Dolan
Section of Hematology/Oncology, Department of Medicine, Committee on Clinical Pharmacology, The University of Chicago, Chicago, Illinois 60637, USA.

Oral oltipraz, as a single-dose treatment, was evaluated as a chemopreventive agent in 31 normal subjects. In a subset of subjects, the relationship between plasma oltipraz concentrations and the induction of lymphocyte glutathione (GSH) and glutathione S-transferase (GST) enzyme levels was evaluated. Pharmacokinetic analysis revealed nonlinear disposition of oltipraz with disproportionate 40-fold increase and 9.5-fold decrease in peak plasma concentrations (Cmax) and p.o. clearance, respectively, over the dose range of 100-500 mg. There was no correlation between the oltipraz dose and the absorption rate or the time to reach Cmax. Since oltipraz undergoes extensive metabolism, saturable first-pass elimination could be one of the sources of nonlinearity. Pharmacodynamic evaluation was conducted based on the percentage of elevation of GSH and GST levels over baseline in lymphocytes of subjects receiving 100 mg and 125 mg oltipraz. Induction was observed in both dose groups with a time lag between the maximum concentrations of oltipraz and that of GSH or GST. We also observed a linear correlation between oltipraz Cmax and the corresponding GSH and GST elevations. Subjects with higher Cmax values showed a greater increase over baseline in the GSH and GST levels. Mild toxicities were observed at all dose levels. The most common were flatulence, hunger, fatigue, and headache. These preliminary results indicate that oltipraz may be effective in inducing GSH and GST, an enzyme capable of carcinogen elimination.

This article has been cited by other articles:

				M. S. Yates, M.-K. Kwak, P. A. Egner, J. D. Groopman, S. Bodreddigari, T. R. Sutter, K. J. Baumgartner, B.D. Roebuck, K. T. Liby, M. M. Yore, et al. Potent Protection against Aflatoxin-Induced Tumorigenesis through Induction of Nrf2-Regulated Pathways by the Triterpenoid 1-[2-Cyano-3-,12-Dioxooleana-1,9(11)-Dien-28-Oyl]Imidazole Cancer Res., February 15, 2006; 66(4): 2488 - 2494. [Abstract] [Full Text] [PDF]

				G. A. Reed, K. S. Peterson, H. J. Smith, J. C. Gray, D. K. Sullivan, M. S. Mayo, J. A. Crowell, and A. Hurwitz A Phase I Study of Indole-3-Carbinol in Women: Tolerability and Effects Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1953 - 1960. [Abstract] [Full Text] [PDF]

				M. J. Kelley, E. M. Glaser, J. E. Herndon II, F. Becker, R. Bhagat, Y.-J. Zhang, R. M. Santella, S. G. Carmella, S. S. Hecht, L. Gallot, et al. Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 892 - 899. [Abstract] [Full Text] [PDF]

				A. Piton, E. Le Ferrec, S. Langouet, C. Rauch, E. Petit, F. Le Goff, A. Guillouzo, and F. Morel Oltipraz regulates different categories of genes relevant to chemoprevention in human hepatocytes Carcinogenesis, February 1, 2005; 26(2): 343 - 351. [Abstract] [Full Text] [PDF]

				B. D. Roebuck, T. J. Curphey, Y. Li, K. J. Baumgartner, S. Bodreddigari, J. Yan, S. J. Gange, T. W. Kensler, and T. R. Sutter Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz Carcinogenesis, December 1, 2003; 24(12): 1919 - 1928. [Abstract] [Full Text] [PDF]

				D. J. Auyeung, F. K. Kessler, and J. K. Ritter Mechanism of Rat UDP-Glucuronosyltransferase 1A6 Induction by Oltipraz: Evidence for a Contribution of the Aryl Hydrocarbon Receptor Pathway Mol. Pharmacol., January 1, 2003; 63(1): 119 - 127. [Abstract] [Full Text] [PDF]

				B. V. Madhukar, N. V. Dimitrov, C. Meyer-Leece, M. L. Contreras, and J. Crowell Inhibition of Mitogen-activated Protein Kinase Activity of Human Lymphocytes after Oral Administration of Oltipraz Mol. Cancer Ther., October 1, 2002; 1(12): 1125 - 1128. [Abstract] [Full Text] [PDF]

				A. Camoirano, M. Bagnasco, C. Bennicelli, C. Cartiglia, J.-B. Wang, B.-C. Zhang, Y.-R. Zhu, G.-S. Qian, P. A. Egner, L. P. Jacobson, et al. Oltipraz Chemoprevention Trial in Qidong, People's Republic of China: Results of Urine Genotoxicity Assays as Related to Smoking Habits Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 775 - 783. [Abstract] [Full Text] [PDF]

				M. Ramos-Gomez, M.-K. Kwak, P. M. Dolan, K. Itoh, M. Yamamoto, P. Talalay, and T. W. Kensler From the Cover: Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice PNAS, March 13, 2001; 98(6): 3410 - 3415. [Abstract] [Full Text] [PDF]

				N. V. Dimitrov, C. M. Leece, E. R. Tompkins, E. Seymour, M. Bennink, J. Gardiner, J. Crowell, E. Hawk, M. Nashawaty, and J. L. Bennett Oltipraz Concentrations in Plasma, Buccal Mucosa Cells,and Lipids: Pharmacological Studies Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 201 - 207. [Abstract] [Full Text]

				L. Pendyala, G. Schwartz, W. Bolanowska-Higdon, S. Hitt, J. Zdanowicz, M. Murphy, D. Lawrence, and P. J. Creaven Phase I/Pharmacodynamic Study of N-Acetylcysteine/Oltipraz in Smokers: Early Termination Due to Excessive Toxicity Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 269 - 272. [Abstract] [Full Text]

				P. J. O’Dwyer, C. Szarka, J. M. Brennan, P. B. Laub, and J. M. Gallo Pharmacokinetics of the Chemopreventive Agent Oltipraz and of Its Metabolite M3 in Human Subjects after a Single Oral Dose Clin. Cancer Res., December 1, 2000; 6(12): 4692 - 4696. [Abstract] [Full Text]

				A. B. Benson III, O. I. Olopade, M. J. Ratain, A. Rademaker, S. Mobarhan, L. Stucky-Marshall, S. French, and M. E. Dolan Chronic Daily Low Dose of 4-Methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in Patients with Previously Resected Colon Polyps and First-Degree Female Relatives of Breast Cancer Patients Clin. Cancer Res., October 1, 2000; 6(10): 3870 - 3877. [Abstract] [Full Text]

				T. K. Bammler, D. H. Slone, and D. L. Eaton Effects of Dietary Oltipraz and Ethoxyquin on Aflatoxin B1 Biotransformation in Non-Human Primates Toxicol. Sci., March 1, 2000; 54(1): 30 - 41. [Abstract] [Full Text] [PDF]

				K. C. Nelson, J. L. Carlson, M. L. Newman, P. Sternberg Jr, D. P. Jones, T. J. Kavanagh, D. Diaz, J. Cai, and M. Wu Effect of Dietary Inducer Dimethylfumarate on Glutathione in Cultured Human Retinal Pigment Epithelial Cells Invest. Ophthalmol. Vis. Sci., August 1, 1999; 40(9): 1927 - 1935. [Abstract] [Full Text] [PDF]

				J.-S. Wang, X. Shen, X. He, Y.-R. Zhu, B.-C. Zhang, J.-B. Wang, G.-S. Qian, S.-Y. Kuang, A. Zarba, P. A. Egner, et al. Protective Alterations in Phase 1 and 2 Metabolism of Aflatoxin B1 by Oltipraz in Residents of Qidong, People's Republic of China J Natl Cancer Inst, February 17, 1999; 91(4): 347 - 354. [Abstract] [Full Text] [PDF]